ClinicalTrials.Veeva

Menu
S

Susquehanna Research Group | Harrisburg, PA

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Etrasimod
ABX464
CIN-102
deudomperidone
Obefazimod
CIN-103
Deudomperidone
Olorinab
Linaprazan Glurate
Lansoprazole

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 18 total trials

A Study Comparing the Effect and Safety of Linaprazan Glurate to Lansoprazole in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD)

The goal of this clinical trial is to find out how well linaprazan glurate can heal erosive esophagitis (EE) caused by gastroesophageal reflux diseas...

Begins enrollment this month
GERD (Gastroesophageal Reflux Disease)
Drug: Linaprazan glurate 50 mg Twice Daily (BID)
Drug: Lansoprazole 30 mg Once Daily (QD)

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help to decrease nausea severity associated with idiopa...

Enrolling
Idiopathic Gastroparesis
Drug: Placebo
Drug: CIN-102 Dose 15mg

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Active, not recruiting
Diabetic Gastroparesis
Drug: Placebo
Drug: CIN-102 Dose 15mg or 10mg

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once d...

Enrolling
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Active, not recruiting
Ulcerative Colitis
Drug: Etrasimod

This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase.The objective is to evaluate...

Enrolling
Moderately to Severely Active Crohn Disease
Drug: Obefazimod
Other: Placebo

The goal of this clinical trial is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with...

Enrolling
Irritable Bowel Syndrome with Diarrhea
Drug: CIN-103
Drug: Placebo

Trial sponsors

A
Pfizer logo
C
A
C
C
C
Exact Sciences Corporation logo
F
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems